MNOV Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -- compared to MediciNova's net margin of -49.65%. MediciNova's return on equity of -- beat NovaBay Pharmaceuticals's return on equity of -461.38%.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 495.24%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 51.84%. Given that MediciNova has higher upside potential than NovaBay Pharmaceuticals, analysts believe MediciNova is more attractive than NovaBay Pharmaceuticals.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. MediciNova's net income of -$2.8M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, MediciNova's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 0.15x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Palatin Technologies has a net margin of -- compared to MediciNova's net margin of -2357.27%. MediciNova's return on equity of -- beat Palatin Technologies's return on equity of --.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 495.24%. On the other hand Palatin Technologies has an analysts' consensus of $7.00 which suggests that it could grow by 1557.59%. Given that Palatin Technologies has higher upside potential than MediciNova, analysts believe Palatin Technologies is more attractive than MediciNova.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.896, suggesting its less volatile than the S&P 500 by 10.45%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Palatin Technologies quarterly revenues of $350K. MediciNova's net income of -$2.8M is lower than Palatin Technologies's net income of -$2.4M. Notably, MediciNova's price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Retractable Technologies has a net margin of -- compared to MediciNova's net margin of -18.58%. MediciNova's return on equity of -- beat Retractable Technologies's return on equity of -16.83%.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 495.24%. On the other hand Retractable Technologies has an analysts' consensus of -- which suggests that it could fall by --. Given that MediciNova has higher upside potential than Retractable Technologies, analysts believe MediciNova is more attractive than Retractable Technologies.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Retractable Technologies has a beta of 2.279, suggesting its more volatile than the S&P 500 by 127.852%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Retractable Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Retractable Technologies pays out -1.94% of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Retractable Technologies quarterly revenues of $10.3M. MediciNova's net income of -$2.8M is lower than Retractable Technologies's net income of -$1.9M. Notably, MediciNova's price-to-earnings ratio is -- while Retractable Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 0.64x for Retractable Technologies. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -- compared to MediciNova's net margin of -9.24%. MediciNova's return on equity of -- beat Vanda Pharmaceuticals's return on equity of -3.49%.

MediciNova has a consensus price target of $8.33, signalling upside risk potential of 495.24%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 190.52%. Given that MediciNova has higher upside potential than Vanda Pharmaceuticals, analysts believe MediciNova is more attractive than Vanda Pharmaceuticals.

MediciNova has a beta of 0.750, which suggesting that the stock is 24.968% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

MediciNova has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MediciNova pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

MediciNova quarterly revenues are --, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. MediciNova's net income of -$2.8M is higher than Vanda Pharmaceuticals's net income of -$4.9M. Notably, MediciNova's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MediciNova is -- versus 1.28x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.